NASDAQ · AXSM
Healthcare · Biotechnology
$174.34
Down-$2.74 (-1.55%)
Updated Oct 7, 2026, 7:04 AM
SID Score
4.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · AXSM
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
AXSM closed at $174.34 after 21 trading sessions, down 16.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $176.52 | $176.52 | $169.30 | $174.34 | 1.37M |
| Oct 5, 2026 | $179.25 | $179.70 | $175.7301 | $177.08 | 858.89K |
| Oct 2, 2026 | $182.55 | $182.55 | $175.455 | $179.25 | 981.38K |
| Oct 1, 2026 | $184.39 | $185.6703 | $181.75 | $182.07 | 660.34K |
| Sep 30, 2026 | $186.51 | $188.00 | $184.00 | $184.39 | 1.03M |
| Sep 29, 2026 | $191.41 | $194.25 | $182.10 | $186.14 | 1.58M |
| Sep 28, 2026 | $194.98 | $198.96 | $193.1101 | $193.89 | 707.41K |
| Sep 25, 2026 | $197.68 | $201.42 | $194.3475 | $195.09 | 838.18K |
| Sep 24, 2026 | $193.02 | $197.11 | $190.72 | $196.03 | 386.18K |
| Sep 23, 2026 | $204.005 | $204.695 | $189.05 | $193.45 | 913K |
| Sep 22, 2026 | $205.68 | $207.01 | $202.52 | $203.10 | 299.79K |
| Sep 21, 2026 | $208.17 | $210.847 | $203.38 | $205.49 | 543.47K |
| Sep 18, 2026 | $212.05 | $213.265 | $206.92 | $207.78 | 869.32K |
| Sep 17, 2026 | $215.59 | $216.47 | $208.6311 | $214.28 | 681.46K |
| Sep 16, 2026 | $202.95 | $214.635 | $201.935 | $211.97 | 645K |
| Sep 15, 2026 | $215.02 | $215.02 | $203.78 | $204.07 | 591.35K |
| Sep 14, 2026 | $221.93 | $223.29 | $216.00 | $216.58 | 718.8K |
| Sep 11, 2026 | $212.71 | $229.62 | $212.44 | $220.75 | 1.23M |
| Sep 10, 2026 | $210.63 | $211.65 | $208.01 | $211.115 | 526.39K |
| Sep 9, 2026 | $207.97 | $211.22 | $205.755 | $210.63 | 428.39K |
| Sep 8, 2026 | $205.00 | $210.855 | $202.00 | $207.82 | 385.78K |
The latest Smart Investors Daily articles mentioning AXSM.
Company
Market Activity
Research & News
AXSM research
Company profile and research snapshot.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Deutsche Bank | Buy | — |
| Sep 25, 2026 | Morgan Stanley | Equal-Weight | — |
| Sep 23, 2026 | Truist Securities | Buy | — |
| Sep 18, 2026 | Piper Sandler | Overweight | — |
| Aug 31, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 1, 2026
Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.
Yahoo · Sep 30, 2026
Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.
Benzinga · Sep 29, 2026
Deutsche Bank analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $280 to $267.
Benzinga · Sep 25, 2026
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AXSM.
